Maximising LDL-Cholesterol Reduction: Integrating Inclisiran With Lipid-Lowering Strategies - 02/04/26
Doi : 10.1016/j.hlc.2025.09.022
Francesco Sbrana, MD ⁎ 
, Beatrice Dal Pino, MD
, Beatrice Dal Pino, MD Lipoapheresis Unit and Reference Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Pisa, Italy
∗ Corresponding author at: Lipoapheresis Unit and Reference Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, 1, 56124 Pisa, Italy Lipoapheresis Unit and Reference Center for Inherited Dyslipidemias Fondazione Toscana Gabriele Monasterio Via Moruzzi 1 Pisa 56124 Italy
Keywords : Alirocumab, Background lipid-lowering treatment, Evolocumab, Inclisiran, LDL-cholesterol target
Le texte complet de cet article est disponible en PDF.
© 2025
Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 35 - N° 4
P. e63-e64 - avril 2026 Retour au numéro
Article précédent
- From PLATO to Practice: The Challenge of Translating Trial Evidence
- Ashish H. Shah
- Corrigendum to: Abstract 727, Vol 34, Supplement 4, Page S567 (2025) (Abstracts for the 73rd Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, 14–17 August 2025) entitled ”Iron Deficiency in Symptomatic Atrial Fibrillation: A Multi-Centre Prospective Observational Study”
- A. Watson, D. Ferreira, A. Chee, A. Balasubramaniam, R. Gleadhill, J. Smiles, S. Jones, K. Cross, A. Albayati, J. Hardy, B. Alabdullah, M. McGee
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?